Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Y-90 SIRT or DEB-TACE in Intermediate Stage HCC
NCT04522544Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2020
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Started Dec 2020; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04522544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522544.